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The adipocyte-derived hormone adiponectin regulates glu-
cose and lipid metabolism and inﬂuences the risk for
developing obesity, type 2 diabetes, and cardiovascular
disease. Adiponectin binds to two different seven-trans-
membrane domain receptors termed AdipoR1 and AdipoR2.
To study the physiological importance of these receptors,
AdipoR1 gene knockout mice (AdipoR1
/) and AdipoR2
gene knockout mice (AdipoR2
/) were generated. Adi-
poR1
/ mice showed increased adiposity associated with
decreased glucose tolerance, spontaneous locomotor activ-
ity, and energy expenditure. However, AdipoR2
/ mice
were lean and resistant to high-fat diet–induced obesity
associated with improved glucose tolerance and higher
spontaneous locomotor activity and energy expenditure
and reduced plasma cholesterol levels. Thus, AdipoR1 and
AdipoR2 are clearly involved in energy metabolism but
have opposing effects. Diabetes 56:583–593, 2007
T
he prevalence of obesity is increasing rapidly,
reaching epidemic proportions in several devel-
oped countries (1–4). Obesity is usually associ-
ated with type 2 diabetes, hypertension, and
dyslipidemia, thereby increasing the risk for coronary
artery disease and mortality (5). The adipose tissue is
important not only because it constitutes the major reser-
voir for energy storage, but also due to the secretion of
factors regulating energy balance in the body (6). The
importance of adipose tissue as an endocrine organ be-
came evident with the identiﬁcation and characterization
of the hormone leptin (7). Leptin suppresses appetite and
increases insulin sensitivity and energy expenditure by
acting both in the hypothalamus (8) and in peripheral
tissues by inhibiting lipid storage (9). Leptin-deﬁcient
(ob/ob) mice or mice lacking a functional leptin receptor
(db/db) are obese, hyperphagic, hyperinsulinemic, and
insulin resistant and have reduced spontaneous locomotor
activity and energy expenditure (6,9).
In 1995, another hormone exclusively secreted by the
adipose tissue termed adiponectin (Acrp30, AdipoQ,
apM1, or GBP28) was characterized independently by four
groups (10–13). Low adiponectin levels are found in
obesity and type 2 diabetes (11,14,15), and reduced adi-
ponectin levels have also been correlated to increased risk
of developing obesity, type 2 diabetes (16,17), and myo-
cardial infarction (18). Adiponectin treatment has both
antidiabetic (19–25) and anti-atherosclerotic (25,26) ef-
fects in animals. Mice deﬁcient in adiponectin are insulin
resistant and prone to develop atherosclerosis (22,27).
Two adiponectin receptors (AdipoR1 and AdipoR2)
have been found. The genes encoding these receptors are
located on different chromosomes, and the gene products
constitute a novel class of seven-transmembrane domain
receptors (28). The immediate downstream signaling
events are largely unknown, but stimulation of the recep-
tors has been shown to activate AMP-activated protein
kinase (AMPK) and induce peroxisome proliferator–acti-
vated receptor  (PPAR) signaling (20,23–25,28).
To study the in vivo importance of these receptors,
AdipoR1 gene knockout mice (AdipoR1
/) and AdipoR2
gene knockout mice (AdipoR2
/) were generated. These
mice were studied in terms of body weight, body fat, food
intake, glucose tolerance, energy expenditure, spontane-
ous locomotor activity, receptor downstream signaling,
and plasma biochemistry.
RESEARCH DESIGN AND METHODS
Creation of AdipoR1 and AdipoR2 gene knockout mice. Heterozygous
AdipoR1 and AdipoR2 gene knockout mice were obtained from Deltagen (San
Carlos, CA). Brieﬂy, the mice were generated by homologous recombination
in 129/OlaHsd ES cells using targeting vectors containing the following
cassette:lacO-spliceacceptor–internalribosomalentrysite–lacZ–polyA–phos-
pho glycerate kinase promoter–neomycin resistance–poly A. This cassette
drives expression of the lacZ gene by the endogenous adiponectin receptor
promoter. AdipoR1
/ mice were created by deleting 105 bp corresponding to
base 107–198 in the AdipoR1 cDNA (Genbank no. BC014875), and AdipoR2
/
mice were created by deleting 1,561 bp corresponding to base 616–802 in the
AdipoR2 cDNA (Genbank no. BC024094). The insertion of the targeting
cassettes did not affect immediate downstream gene expression in either of
the knockouts (data not shown), indicating that the phenotypes of the two
receptor knockouts are not due to interference with expression of ﬂanking
genes. The mouse models were generated by breeding chimeras carrying a
disrupted AdipoR1 or AdipoR2 gene with C57BL/6 females, resulting in F1
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females for seven (AdipoR1) or six (AdipoR2) generations before intercross-
ing. Both intercrosses resulted in normal litter sizes and Mendelian distribu-
tion of genotypes (data not shown). All experiments in this study were
performed using littermate wild-type mice as controls. Genotyping was done
by a PCR strategy. For the AdipoR1 gene, one primer was located upstream of
the deleted region in the short arm (5AGGCAGGGTAAGCTGATTAGCTATG
3), a second primer located in exon 2 (5 TCCACTGTGTCAGCTTCTCTG
TTAC 3), and a third located in the targeting cassette (5 GGGTGGGATTAG
ATAAATGCCTGCTCT 3). For the AdipoR2 gene, one primer was located
upstream of the deleted region in the short arm (5GACGGAGTTTGTATGTG
GTAGCGTC 3), a second primer was located in exon 5 (5 TCTCTGCCTTT
CCTTTTCATGGCTC 3), and a third was located in the targeting cassette (5
GGGCCAGCTCATTCCTCCCACTCAT 3).
Diets, body weight, food intake, body composition, fecal energy con-
tent, and termination. The mice were given either standard laboratory chow
containing (energy percentage) 12% fat, 62% carbohydrates, and 26% protein,
with a total energy content of 12.6 kJ/g (R3; Lactamin, Kimstad, Sweden) or a
high-fat diet (HFD) containing 39.9% fat (mainly saturated), 42.3% carbohy-
drates, and 17% protein with a total energy content of 21.4 kJ/g and
supplemented with 0.15% cholesterol (R638; Lactamin). Mice were weighed
weekly after 5 weeks of age. Food intake was analyzed for 24 h in food-
deprived (12 h) mice housed individually as described before (29). Body
composition analysis was performed on isoﬂurane (Forene; Abbot, Scandina-
via, Sweden)-anesthetized mice by dual-energy X-ray absorptiometry (DEXA)
(PIXImus Lunar; GE Medical Systems, Madison, WI). Feces from the animals
were dried at 55°C overnight and stored in airtight containers at 20°C until
assayed. The gross energy content of the fecal pellets was determined using a
bomb calorimeter (C5000; IKA, Werke, Staufen, Germany). At termination
(9–11 A.M.), plasma was isolated from isoﬂurane-anesthetized mice and organs
collected, weighed, snap frozen in N2, and stored at 80°C. Experimental
procedures were approved by the local ethics review committee on animal
experiments (Gothenburg region).
Indirect calorimetry and activity. Oxygen consumption (VO2) and carbon
dioxide production (VCO2) were measured using an open-circuit calorimetry
system (Oxymax; Columbus Instruments International, Columbus, OH) as
described before (29). Energy expenditure (in kilocalories per hour) was
calculated as follows: (3.815  1.232 RER)  VO2, where RER is the
respiratory exchange ratio (volume of CO2 produced per volume of O2
consumed [both in ml/kg/min]) and VO2 is the volume of O2 consumed per
hour per kilogram of mass of the animal. The value of energy expenditure was
correlated with individual body weights. Locomotor and rearing activity and
corner time were measured in activity boxes (Kungsbacka ma ¨t-och reg-
lerteknik, Kungsbacka, Sweden) over 1 h, 10:00–11:00 A.M., on 2 consecutive
days.
Oral glucose tolerance test. Oral glucose tolerance tests were performed
12.30 h after a 4-h fast by oral administration of 2 g glucose/kg body wt. Blood
(12 l) was sampled from the tail vein at 0, 15, 30, 60, 90, and 120 min for
determination of glucose (2 l, Accu-Chek; Roche Diagnostics, Mannheim,
Germany) and insulin (2  5 l, Ultra-sensitive rat insulin ELISA kit; Crystal
Chem, Downers Grove, IL) levels.
Blood biochemistry and liver triglyceride content. Plasma adiponectin
was measured using a radioimmunoassay from Linco Research (St. Charles,
MO) and plasma leptin with an ELISA from Chrystal Chem. Total plasma
thyroxine (T4), triiodothyronine (T3), and testosterone levels were determined
using radioimmunoassays (Coat-A-Count; Diagnostic Products, Los Angeles,
CA). Plasma cholesterol and triglyceride levels were measured with enzymatic
colorimetric assays (Roche Diagnostics). The cholesterol distribution proﬁles
were measured using a size-exclusion high-performance liquid chromatogra-
phy system, SMART, with column Superose 6 PC 3.2/30 (Amersham Pharma-
cia Biotech), as described before (30). The lipoproteins in a 10-l sample were
separated within 60 min, and the area under the curves represents the
cholesterol content. Liver triglyceride content was measured after homogeni-
zation in isopropanol (1 ml/50 mg), incubation at 4°C for 1 h, and centrifuga-
tion at 2,500 rpm for 5 min.
Histology. Tissues were ﬁxed in 4% buffered paraformaldehyde, embedded in
parafﬁn, sectioned, and stained with hematoxylin and eosin or -galactosi-
dase. For electron microscopy, ﬁxated sections were treated with osmium,
dehydrated in graded ethanol (70, 85, 95, and 100%) and propylene oxide, and
embedded in TAAB 812 (TAAB Laboratories, Berkshire, England).
RNA preparation and quantitative real-time PCR. Total RNA was ex-
tracted using Trizol (Invitrogen, Carlsbad, CA). First-strand cDNA was syn-
thesized from DNAse-treated total RNA using the High-Capacity cDNA
Archive Kit (Applied Biosystems, Foster City, CA). Real-time PCR analysis
was performed with an ABI Prism 7900 Sequence Detection System using
FAM- and TAMRA-labeled ﬂuorogenic probes or the SYBR-Green detection
system (Applied Biosystems). Expression data were normalized against
mouse acidic ribosomal phosphoprotein P0 (m36B4). The relative expression
levels were calculated according to the formula 2
CT, where CT is the
difference in cycle threshold values between the target and the m36B4 internal
control. Sequences for primers and probes are presented in supplemental
Table 1 (available in an online appendix at http://dx.doi.org/10.2337/db06-
1432).
Immunoblotting. Antibodies against human AdipoR1 and AdipoR2 were
generated by immunizing rabbits with either of the following peptides:
GAPASNREADTVELAELGP (AdipoR1) and CSRTPEPDIRLRKGHQLDG
(AdipoR2). These sequences had 89% (AdipoR1) and 94% (AdipoR2) homology
with the corresponding mouse sequences. The antibodies were afﬁnity puri-
ﬁed and used at 1 g/ml in phosphate-buffered saline with Tween, 5% milk
powder. Tissues were homogenized in 10 mmol/l Hepes-KOH (pH 7.4), 2
mmol/l EDTA, 40 mmol/l sucrose, and 125 mmol/l mannitol in the presence of
protease inhibitors and centrifuged at 800g to remove the nuclei. The
supernatant was collected and centrifuged at 100,000g to collect total mem-
branes. Phosphorylation and protein levels of AMPK1 were determined as
described (31) using AMPK1 antibodies from Upstate Cell Signaling (Lake
Placid, NY) and phospho AMPK (Thr172) antibodies from Cell Signaling
Technology (Danvers, MA).
Statistics. Values are presented as means 	 SEM. Differences between two
groups were examined for statistical signiﬁcance using Mann-Whitney U test.
For multiple groups, P values were calculated using the MIXED procedure in
SPSS. A mixed ANOVA model is assumed with treatment and time as factors
and their interaction as ﬁxed effects and subject within treatment group as
random effects. Each P value corresponds to a test of no difference between
treatments at the speciﬁed time point, derived from the corresponding
contrast in the ANOVA model.
RESULTS
AdipoR1-deﬁcient mice show increased adiposity.
AdipoR1
/ mice were created by exchanging part of
exon 2 with a targeting vector containing LacZ and Neo-
mycin resistance genes (Fig. 1A). Wild-type controls, mice
heterozygous for the AdipoR1 gene, and AdipoR1
/ mice
were genotyped with PCR (Fig. 1B). The absence of
AdipoR1 protein in AdipoR1
/ mice was conﬁrmed by
immunoblot analysis of brain (Fig. 1C) and quadriceps
skeletal muscle (Supplemental Fig. 1A [available at http://
dx.doi.org/10.2337/db06-1432]) protein preparations. Male
but not female AdipoR1
/ mice had increased body
weight gain (Fig. 1D and E) in spite of food intake similar
to that of wild-type controls (data not shown). Further-
more, male AdipoR1
/ mice had increased total body fat
mass at 15 weeks of age, as determined by DEXA (Fig. 1F).
At 31 weeks of age, AdipoR1
/ mice had increased
reproductive white adipose tissue (WAT), perirenal WAT,
and brown adipose tissue (BAT) weights (Fig. 1G). In line
with the increased fat mass, AdipoR1
/ mice tended to
have higher plasma leptin levels than wild-type controls,
while plasma adiponectin levels were unchanged (Table
1). Thus, AdipoR1 deﬁciency results in increased fat mass.
AdipoR1-deﬁcient mice have decreased glucose tol-
erance. Male AdipoR1
/ mice had decreased glucose
tolerance as determined by oral glucose tolerance testing
(Fig. 1H). The area under the curve for the glucose
response was 34% higher (P 
 0.05) in AdipoR1
/ mice
compared with wild-type controls. The insulin response
was not signiﬁcantly altered (Fig. 1H). AdipoR1
/ fe-
males had 22% higher fasting glucose levels (wild-type
7.68 	 0.42 mmol/l and AdipoR1
/ 9.37 	 0.44 mmol/l,
P 
 0.05, n  4–7) but unchanged fasting insulin levels
(wild-type 0.53 	 0.06 g/l and AdipoR1
/ 0.73 	 0.11
g/l, n  4–7). Thus, AdipoR1 deﬁciency leads to de-
creased glucose tolerance. AdipoR1 deﬁciency did not
affect plasma triglyceride levels, but plasma cholesterol
levels were elevated in AdipoR1
/ females compared
with wild-type controls. In addition, liver triglyceride
ADIPONECTIN RECEPTOR DEFICIENCY
584 DIABETES, VOL. 56, MARCH 2007FIG. 1. Creation and phenotype of AdipoR1 gene knockout mice (R1
/). A: Part of exon 2 in the AdipoR1 gene was homologously replaced with
a targeting vector containing lacZ-Neo genes. B: Wild-type (wt) mice, mice heterozygous for the AdipoR1 gene (R1
/), and R1
/ were genotyped
with PCR. C: Lack of AdipoR1 protein in R1
/ was conﬁrmed using immunoblot analysis of brain protein preparations. AMPK1 subunit served
as loading control. D: Body weight curves for males fed regular chow (n  5–8) and representative image of 31-week-old R1
/ and wild-type male
mice. E: Body weight curves for females (n  4–7). F: Quantitative assessment of body fat mass by DEXA on 28-week-old R1
/ and wild-type
males (n  5–8). G: Dissected reproductive (Repr.) WAT, perirenal (Per.) WAT, and BAT from 31-week-old males and females (n  8–14). H: Oral
glucose tolerance test on 30-week-old R1
/ and wild-type males (n  4–7). Values are means  SEM. *P < 0.05, **P < 0.01, Mann-Whitney U test.
M. BJURSELL AND ASSOCIATES
DIABETES, VOL. 56, MARCH 2007 585content tended to be increased in AdipoR1
/ mice com-
pared with wild-type controls (Table 1).
Effects of AdipoR1-deﬁciency on AMPK and PPAR
signaling and AdipoR2 expression. Adiponectin treat-
ment may increase insulin sensitivity by stimulating fatty
acid oxidation via AMPK (23,24,28) and PPAR activation
(20,25,28) in liver and skeletal muscle. The expression of
PPAR mRNA was unchanged, and its downstream target
gene carnitine palmitoyl transferase-1 (CPT-1) was in-
creased in AdipoR1
/ livers compared with wild-type
controls, while PPAR or CPT-1 mRNA levels did not
differ between the genotypes in skeletal muscle (Supple-
mental Fig. 1B). In addition, AdipoR1
/ mice did not
show changed phosphorylation of AMPK in liver, skeletal
muscle, or heart (Supplemental Fig. 1C). Thus, Adi-
poR1
/ mice do not have decreased glucose tolerance as
a result of changed PPAR activity or basal AMPK phos-
phorylation. AdipoR1
/ mice showed increased AdipoR2
mRNA expression in BAT, while it was unchanged in WAT,
skeletal muscle, and brain. In addition, both mRNA and
protein levels of AdipoR2 tended to be elevated in
AdipoR1
/ livers (Supplemental Fig. 1D and E). Thus,
AdipoR1
/ deﬁciency results in higher expression of
AdipoR2 in liver and BAT but not in WAT, skeletal muscle,
or brain.
AdipoR1-deﬁcient mice show decreased energy ex-
penditure and locomotor activity. AdipoR1
/ mice
had decreased energy expenditure but unchanged respira-
tory exchange ratio compared with wild-type controls
(Fig. 2A). The decreased energy expenditure in Adi-
poR1
/ mice was observed during both the light and dark
phase of the 24-h period. AdipoR1
/ mice had decreased
spontaneous locomotor activity and increased time spent
in the corners of the cages (Fig. 2B). The decreased
activity in AdipoR1
/ mice was not due to alterations in
plasma levels of thyroid hormones (T3 or T4) (Table 1).
Thus, the increased fat mass in AdipoR1
/ is due to
decreased energy expenditure. Decreased spontaneous
locomotor activity could contribute to the decreased en-
ergy expenditure.
AdipoR2-deﬁcient mice show resistance to HFD-
induced obesity. AdipoR2
/ mice were created by
exchanging exon 5 with a targeting vector containing LacZ
and Neomycin resistance genes (Fig. 3A). Wild-type con-
trols, mice heterozygous for the AdipoR2 gene, and
AdipoR2
/ mice, were genotyped with PCR (Fig. 3B).
The absence of AdipoR2 protein in AdipoR2
/ mice was
conﬁrmed by immunoblot analysis of liver (Fig. 3C) and
quadriceps skeletal muscle (Supplemental Fig. 2A) protein
preparations. Surprisingly, both male and female
AdipoR2
/ mice were lean on regular chow and resistant
to HFD-induced weight gain (Fig. 3D and E). The resis-
tance was not due to decreased food intake. If anything, a
trend toward increased food intake (28%) was observed in
female AdipoR2
/ mice compared with wild-type con-
trols given HFD (Supplemental Fig. 2B). In accordance
with a higher food intake, the hypothalamic mRNA levels
of the orexigenic peptides agouti-related peptide (AGRP)
and neuropeptide Y (NPY) were increased by 150 and
60%, respectively (Supplemental Fig. 2C), while the ex-
pression of another orexigenic peptide, melanin-concen-
trating hormone, was unchanged in female AdipoR2
/
mice (data not shown). Intracerebroventricular adminis-
tration of adiponectin has been shown to increase the
hypothalamic expression of the anorexigenic corticotro-
phin-releasing hormone (CRH) (32). AdipoR2
/ mice had
48% increased hypothalamic mRNA levels of CRH (Sup-
plemental Fig. 2C). AdipoR2
/ mice did not show any
signs of malabsorption. The total fecal energy output
measured over 48 h was not different between AdipoR2
/
mice and wild-type controls (data not shown). Thus,
AdipoR2
/ mice were resistant to HFD-induced weight
gain in spite of a trend toward increased food intake and
unchanged fecal energy loss.
After 8 weeks of HFD, female AdipoR2
/ mice had
markedly lower total body fat mass and moderately lower
lean body mass compared with wild-type controls as
determined by DEXA (Fig. 3G). However, crown-rump
length was not different (data not shown). After 11 weeks
FIG. 2. Energy expenditure and spontaneous locomotor activity of
AdipoR1 knockout mice (R1
/). A: Energy expenditure and respira-
tory exchange ratio measured with an open circuit calorimetry system
in 28-week-old R1
/ and wild-type males (dark period shaded, n 
5–7). B: Locomotor activity and corner time measured with activity
boxes in 29-week-old R1
/ and wild-type males (n  5–7). a.u.,
arbitrary units; N.S., nonsigniﬁcant. Values are means  SEM. A mixed
ANOVA was used for statistical analyses.
TABLE 1
Plasma biochemistry and liver triglyceride content in AdipoR1 gene knockout mice (R1
/)
n
Leptin
(ng/ml)
Adiponectin
(nmol/l)
Cholesterol
(mmol/l)
Triglycerides
(mmol/l)
Liver triglycerides
(% liver wt)
T3
(nmol/l)
T4
(nmol/l)
Males
Wild-type 4 3.5 	 0.7 611 	 60 3.0 	 0.3 1.0 	 0.2 3.13 	 0.19 1.1 	 0.0 55.6 	 4.1
R1
/ 8 4.8 	 1.7 574 	 31 3.4 	 0.3 0.9 	 0.1 4.75 	 1.25 1.2 	 0.1 52.4 	 2.0
Females
Wild-type 4 2.5 	 0.9 782 	 148 2.2 	 0.1 0.7 	 0.1 3.88 	 0.61 ND ND
R1
/ 7 6.2 	 1.1 1,064 	 140 3.7 	 0.4* 1.0 	 0.2 6.30 	 1.22 ND ND
Data are means 	 SEM. The mice were 31 weeks old. Plasma levels of leptin, adiponectin, cholesterol, triglycerides, liver triglyceride content,
T3, and T4 were measured as described in RESEARCH DESIGN AND METHODS. ND, not determined. *P 
 0.05, Mann Whitney U test.
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586 DIABETES, VOL. 56, MARCH 2007FIG. 3. Creation, body weight-gain, histological analyses, and body fat mass assessment of AdipoR2 gene knockout mice (R2
/). A: Exon 5 in the
AdipoR2 gene was homologously replaced with a targeting vector containing lacZ-Neo genes. B: Wild-type (wt) mice, mice heterozygous for the
AdipoR2 gene (R2
/), and R2
/ were genotyped with PCR. C: Lack of AdipoR2 protein in R2
/ was conﬁrmed using immunoblot analysis of liver
protein preparations. AMPK1 served as loading control (upper band). D: Body weight curves for males fed regular chow or HFD (n  5). E: Body
weight curves for females fed regular chow or HFD (n  5–10) and representative image of R2
/ and wild-type females after 14 weeks of HFD.
F: Representative histology of testes from 15-week-old males on regular chow, WAT, and BAT from 33-week-old females fed HFD for the last 14
weeks. G: Quantitative assessment of body fat and lean mass by DEXA on 32-week-old R2
/ and wild-type females fed HFD for the last 13 weeks
(n  10). H: Representative histology and -galactosidase staining of brains. Values are means  SEM. *P < 0.05, **P < 0.01, Mann-Whitney U
test.
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/ mice had markedly less reproductive
WAT (males 55% and females 67%), perirenal WAT
(males 53% and females 69%), and BAT (males 44%
and females 26%) weights and plasma levels of leptin
(70% in both males and females) compared with corre-
sponding wild-type controls (Table 2 and 3). After 14
weeks of HFD, female AdipoR2
/ adipocytes in WAT
were smaller in size and their BAT contained less vacuoles
than wild-type controls (Fig. 3F). Female AdipoR2
/
mice had lower liver triglyceride content when fed regular
chow and a trend toward decreased levels after HFD
compared with wild-type controls. In addition, male Adi-
poR2
/ mice had markedly lower liver triglyceride con-
tent (61%) than wild-type controls when fed HFD (Table
3). Plasma levels of adiponectin tended to be elevated in
AdipoR2
/ mice and was signiﬁcantly elevated in female
AdipoR2
/ mice on regular chow (Table 3). In summary,
AdipoR2
/ mice were lean and resistant to HFD-induced
body weight gain, obesity, and hepatic steatosis.
AdipoR2-deﬁcient mice have reduced testes weight
and increased brain weight. From extensive weighing
and histological microscopic examination of 40 different
tissues, testes weight was found to be reduced in
AdipoR2
/ males compared with wild-type controls. This
weight reduction was associated with an atrophy of the
seminiferous tubules and aspermia (Fig. 3F) but no signif-
icant change in plasma testosterone levels (data not
shown). Because of the testicular phenotype of Adi-
poR2
/ males, female AdipoR2
/ mice were analyzed in
more detail.
Interestingly, both male and female AdipoR2
/ mice
had higher brain weight compared with wild-type controls
(Table 2). In addition, the whole AdipoR2
/ brain was
stained with -galactosidase, demonstrating a general ex-
pression of AdipoR2 in the brain (Fig. 3H). Gross histo-
logical examination did not reveal any major differences in
the morphology of the brain. AdipoR1 deﬁciency did not
TABLE 2
Organ weights of AdipoR2 gene knockout mice (R2
/)
n
Reproductive WAT
(% body wt)
Perirenal WAT
(% body wt)
BAT
(% body wt)
Brain
(% body wt)
Brain
(g)
Males
Chow fed
Wild-type 6 3.25 	 0.43 1.06 	 0.18 0.44 	 0.03 1.46 	 0.06 0.465 	 0.005
R2
/ 7 2.36 	 0.23 0.69 	 0.09 0.44 	 0.05 1.69 	 0.06 0.502 	 0.007*
HFD fed
Wild-type 5 6.25 	 0.17 1.89 	 0.09 0.95 	 0.06 1.08 	 0.04 0.459 	 0.005
R2
/ 5 2.79 	 0.25* 0.89 	 0.11* 0.53 	 0.06* 1.66 	 0.08* 0.500 	 0.009†
Females
Chow fed
Wild-type 6 4.28 	 0.64 0.67 	 0.11 0.37 	 0.03 1.89 	 0.09 0.475 	 0.005
R2
/ 6 2.15 	 0.16* 0.29 	 0.03* 0.32 	 0.02 2.32 	 0.03* 0.520 	 0.005*
HFD fed
Wild-type 6 8.87 	 0.61 1.40 	 0.09 0.43 	 0.01 1.43 	 0.07 0.457 	 0.013
R2
/ 6 2.90 	 0.34* 0.44 	 0.07* 0.32 	 0.02* 2.31 	 0.06* 0.508 	 0.007*
Data are means 	 SEM. The mice were 33 weeks old and fed normal chow or HFD for the last 11 weeks. Reproductive WAT, perirenal WAT,
BAT, and brain were weighed and presented as grams or percentage of body weight. *P 
 0.01, †P 
 0.05, Mann Whitney U test.
TABLE 3
Liver triglyceride content and plasma biochemistry in AdipoR2 gene knockout mice (R2
/)
n
Liver
triglycerides
(% liver wt)
Leptin
(ng/ml)
Adiponectin
(nmol/l)
Cholesterol
(mmol/l)
Triglycerides
(mmol/l)
T3
(nmol/l)
T4
(nmol/l)
Males
Chow fed
Wild-type 6 1.65 	 0.22 5.8 	 1.5 294 	 21 2.6 	 0.2 1.3 	 0.2 ND ND
R2
/ 7 1.51 	 0.29 3.5 	 0.5 344 	 38 2.2 	 0.1* 1.0 	 0.1 ND ND
HFD fed
Wild-type 5 6.67 	 1.30 21.1 	 2.6 308 	 26 5.6 	 0.3 0.9 	 0.2 ND ND
R2
/ 5 2.58 	 0.29† 6.4 	 1.2† 321 	 14 3.0 	 0.2† 0.9 	 0.1 ND ND
Females
Chow fed
Wild-type 6 2.88 	 0.32 3.9 	 0.9 493 	 13 1.8 	 0.1 0.7 	 0.2 1.0 	 0.06 71.6 	 4.8
R2
/ 6 1.69 	 0.16* 2.1 	 0.3 569 	 17† 1.5 	 0.1* 0.7 	 0.1 1.0 	 0.04 64.3 	 3.2
HFD fed
Wild-type 6 5.29 	 0.76 11.5 	 2.3 558 	 94 3.2 	 0.3 0.3 	 0.04 1.4 	 0.08 88.1 	 6.8
R2
/ 6 4.46 	 0.63 3.1 	 0.6† 602 	 42 1.9 	 0.1† 0.4 	 0.05 1.2 	 0.02 78.5 	 4.2
Data are means 	 SEM. The mice were 33 weeks old and fed normal chow or HFD the last 11 weeks. Liver triglyceride content and plasma
levels of leptin, adiponectin, cholesterol, triglycerides, T3, and T4 were measured as described in RESEARCH DESIGN AND METHODS. ND, not
determined. *P 
 0.05, †P 
 0.01, Mann Whitney U test.
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speciﬁc importance for brain growth.
AdipoR2-deﬁcient mice have improved glucose toler-
ance. On HFD, female AdipoR2
/ mice had 76% lower
fasting insulin levels (P 
 0.01) and lower insulin and
glucose response following an oral glucose tolerance test
(Fig. 4A). The area under the curve for the insulin re-
sponse was 70% lower (P 
 0.01) and the glucose response
9% lower (P 
 0.05) in AdipoR2
/ mice compared with
wild-type controls. Thus, AdipoR2
/ mice had improved
glucose tolerance compared with wild-type controls.
AdipoR2-deﬁcient mice have decreased plasma cho-
lesterol levels. AdipoR2
/ mice had reduced total
plasma cholesterol levels irrespective of diet, while
plasma triglyceride levels were unchanged (Table 3). The
decreased plasma cholesterol levels were mainly ex-
plained by lower HDL levels (Fig. 4B). In addition, plasma
apolipoprotein AI (apoAI) levels were reduced in
AdipoR2
/ mice compared with wild-type controls (Fig.
4C), while liver apoAI mRNA expression was unchanged
(data not shown). Liver-speciﬁc reduction of ATP binding
cassette transporter-1 (ABCA1) has been shown to de-
crease HDL cholesterol and apoAI levels (33). In line with
this, AdipoR2
/ mice had lower ABCA1 mRNA levels
in the liver than wild-type controls (Fig. 4D). Thus,
AdipoR2
/ mice have reduced plasma HDL cholesterol and
apoAI levels associated with reduced liver ABCA1 mRNA
expression.
Effects of AdipoR2 deﬁciency on AMPK and PPAR
signaling and AdipoR1 expression. AdipoR2
/ mice
had decreased AdipoR1 mRNA levels in liver and BAT,
while the expression was unchanged in WAT, skeletal
muscle, and brain compared with wild-type controls (Sup-
plemental Fig. 2D). AdipoR2
/ mice had increased Adi-
poR1 protein levels in BAT and skeletal muscle and a trend
toward lower levels in liver (Supplemental Fig. 2E). Thus,
AdipoR1 protein and mRNA levels were regulated differ-
ently in BAT and skeletal muscle. The mRNA expression
of PPAR and CPT-1 were downregulated in AdipoR2
/
livers, while AdipoR2
/ mice and wild-type controls had
similar levels of PPAR and CPT-1 in skeletal muscle
(Supplemental Fig. 2F). AdipoR2
/ mice did not show
increased phosphorylation of AMPK in liver, skeletal mus-
cle, or heart (Supplemental Fig. 2G). Thus, enhanced
PPAR or AMPK phosphorylation cannot explain the fact
that AdipoR2
/ mice are lean and have improved glucose
tolerance. However, the results supports a speciﬁc role of
AdipoR2 in the regulation of hepatic PPAR signaling,
since PPAR signaling is increased in AdipoR1
/ livers,
where AdipoR2 is elevated (Supplemental Fig. 1B), and
decreased in AdipoR2-deﬁcient livers (Supplemental Fig.
2F).
AdipoR2-deﬁcient mice show increased energy ex-
penditure and locomotor activity. On HFD, female
AdipoR2
/ mice had increased energy expenditure but
unchanged respiratory exchange ratio compared with
wild-type controls (Fig. 5A). The increased energy expen-
diture in AdipoR2
/ mice was observed both during
the light and dark phase of the measured period. The
AdipoR2
/ mice had markedly increased locomotor and
rearing activity at the expense of decreased corner time
in activity boxes in both female (Fig. 5B) and male
AdipoR2
/ mice (Supplemental Fig. 3). The increased
activity in AdipoR2
/ mice was not explained by alter-
ations in plasma levels of T3 or T4 (Table 3). AdipoR2
/
BAT contained more and larger mitochondria, indicating a
more active tissue compared with wild-type controls (Fig.
5C). In contrast, AdipoR1
/ mice had no histological
changes in BAT (data not shown). Thus, AdipoR2
/ mice
are protected from HFD-induced obesity and have in-
creased energy expenditure and spontaneous locomotor
activity.
DISCUSSION
Adiponectin is a hormone produced exclusively in adipo-
cytes that has both antidiabetes (19–25) and anti-athero-
sclerotic (25,26) properties. Thus, it was anticipated that
depletion of either of its two receptors (28) would result in
a phenotype similar to that of adiponectin deﬁciency
FIG. 4. Oral glucose tolerance, cholesterol distribution proﬁle, plasma
Apo AI levels, and liver ABCA1 mRNA expression in AdipoR2 knock-
out mice (R2
/). A: Oral glucose tolerance test on 28-week-old R2
/
and wild-type females fed HFD for the last 8 weeks (n  6). B:
Cholesterol distribution proﬁles were measured from individual mice
with a size exclusion HPLC system. C: Plasma Apo AI was measured
with immunoblot analysis. D: Liver ABCA1 mRNA expression was
measured with quantitative real-time PCR. B–D: 33-week-old R2
/ and
wild-type females fed HFD for the last 14 weeks (n  5–8). a.u.,
arbitrary units. Values are means  SEM. *P < 0.05, Mann-Whitney U
test.
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became obese and glucose intolerant. However, AdipoR2
deﬁciency resulted in a lean phenotype and resistance to
diet-induced obesity associated with improved glucose
tolerance and decreased plasma cholesterol levels. The
remarkable opposite phenotypes of the two adiponectin
receptor knockout mice were associated with opposite
effects on energy expenditure and physical activity.
AdipoR1 deﬁciency resulted in decreased energy expendi-
ture and spontaneous locomotor activity, while AdipoR2
deﬁciency had the opposite effect. Thus, AdipoR1 and
AdipoR2 are truly yin yang receptors in energy metabolism.
Adiponectin treatment has been reported to cause
weight loss in mice (19,32). However, adiponectin deﬁ-
ciency is not associated with changes in body weight or
obesity (22). AdipoR1 deﬁciency resulted in increased
body weight and obesity, which is in line with AdipoR1
mRNA levels in adipose tissue being negatively correlated
with BMI in humans (34). The obese phenotype of
AdipoR1
/ mice was associated with decreased whole-
FIG. 5. Energy expenditure, spontaneous locomotor activity, and BAT morphology in AdipoR2 knockout mice (R2
/). A: Energy expenditure and
respiratory exchange ratio measured with an open circuit calorimetry system in 32-week-old R2
/ and wild-type females fed HFD for the last 13
weeks (dark period shaded, n  8). B: Locomotor and rearing activity and corner time measured with activity boxes in 26-week-old R2
/ and
wild-type females fed HFD for the last 6 weeks (n  6). a.u., arbitrary units. C: Electron microscopy of BAT from representative 33-week-old
R2
/ and wild-type females fed HFD for the last 14 weeks. m, mitochondria. Values are means  SEM. A mixed ANOVA was used for statistical
analyses. N.S., nonsigniﬁcant.
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versely, the resistance to diet-induced obesity in
AdipoR2
/ mice was associated with increased energy
expenditure and locomotor activity. Intracerebroventricu-
lar administration of adiponectin in mice has been shown
to decrease body weight by elevating energy expenditure
(32). Furthermore, AdipoR2
/ mice showed increased
mitochondrial content in BAT, indicating that the fatty
acid oxidation is upregulated in BAT. Incubation of human
skeletal muscle cells with adiponectin was recently shown
to stimulate mitochondrial biogenesis (35). Thus, the
phenotype of the AdipoR2
/ mice is similar to that
observed following adiponectin treatment. Moreover, from
the present results it could be speculated that the lack of
effect of adiponectin deﬁciency on adiposity could be due
to a similar decrease in AdipoR1 and AdipoR2 signaling.
Interestingly, AdipoR2 was generally expressed in the
entire brain in accordance with previous studies measur-
ing AdipoR2 mRNA levels (28,36). It is debated whether
adiponectin crosses the blood-brain barrier (32,37). Thus,
the effect of AdipoR2 deﬁciency on brain size could be due
to altered adiponectin signaling via direct or indirect
mechanisms (32,37) or alternatively via another yet un-
identiﬁed factor interacting with AdipoR2 in the brain.
Future studies need to explore the physiological impor-
tance of AdipoR2 in the brain. It may be speculated that
the corticolimbic dopamine and reward mechanisms (38)
are important for the observed effects on energy expendi-
ture and spontaneous locomotor activity. Interestingly, in
animal models of obesity such as ob/ob mice, obese Zucker
rats, and obese-prone Sprague-Dawley rats, dopamine
activity is reduced and obesity reversed upon treatment
with dopamine agonists (39). In addition, hyperactive and
lean melanin-concentrating hormone-1 receptor–deﬁ-
cient mice (MCHR1
/) have upregulated dopamine re-
ceptors (40). Despite a decreased body weight and obesity,
AdipoR2
/ mice had a trend toward increased food
intake in combination with increased expression levels of
the orexigenic hypothalamic peptides NPY and AGRP.
This resembles the phenotype of the MCHR1
/ mice,
which are hyperphagic but lean due to increased energy
expenditure (41,42). Thus, the increased energy expendi-
ture during the entire 24-h period measured in AdipoR2
/
mice overrides an effect of increased food intake on body
weight in these mice. It is interesting that AdipoR2 deﬁ-
ciency has the same stimulatory effect on CRH level in
hypothalamus as intracerebroventricular injection of adi-
ponectin (32). CRH is known to be anorexigenic and to
increase energy expenditure (8). Thus, in spite of increased
expression of orexigenic NPY and AGRP and a trend toward
increased food intake, AdipoR2
/ mice are lean due to
increased energy expenditure associated with increased
anorexigenic CRH expression in the hypothalamus.
Similar to adiponectin deﬁciency (22,27), AdipoR1 deﬁ-
ciency lead to decreased glucose tolerance, indicating
decreased insulin sensitivity. In line with this ﬁnding,
single nucleotide polymorphisms (SNPs) in ADIPOR1
have been correlated with decreased glucose tolerance
also in humans (43). Similar to adiponectin treatment
(20,21), AdipoR2
/ mice showed improved glucose tol-
erance and lower insulin response, indicating improved
insulin sensitivity. The opposite effect on glucose toler-
ance in AdipoR1
/ and AdipoR2
/ mice could be either
direct or indirect effects via differences in obesity. Inter-
estingly, 3-adrenoceptor agonist treatment of db/db mice
improved glucose tolerance in association with decreased
hepatic AdipoR2 levels (44), indicating that lower expres-
sion of AdipoR2 is beneﬁcial for glucose homeostasis. In
addition, AdipoR2
/ mice had markedly lower plasma
levels of leptin following HFD compared to wt controls.
This ﬁnding indicates improved leptin sensitivity in
AdipoR2
/ mice that may help to explain the resistance
to HFD-induced obesity and improved glucose tolerance
and increased energy expenditure (9). Moreover, it was
recently shown that SNPs in ADIPOR2 were linked to type
2 diabetes (45), indicating that AdipoR2 affects insulin
sensitivity also in humans.
Female AdipoR1
/ mice showed increased plasma
cholesterol levels. However, AdipoR2 deﬁciency resulted
in decreased plasma cholesterol levels mainly in the HDL
fraction. Recently, an SNP cluster in ADIPOR2 was shown
to be associated with decreased VLDL cholesterol levels
(46), indicating that decreased AdipoR2 levels may be
associated with decreased VLDL and not HDL cholesterol
levels in humans. Whether AdipoR2 deﬁciency will be
protective against atherosclerosis similar to adiponectin
treatment (25) remains to be investigated.
It is difﬁcult to understand the similar phenotype of
adiponectin treatment and AdipoR2 deﬁciency, since
AdipoR2 has been shown to be activated by adiponectin
(28). One explanation for the opposing effects of AdipoR1
and AdipoR2 deﬁciency could be receptor signaling.
AdipoR1 has been shown to bind globular adiponectin
with higher afﬁnity than full-length adiponectin, while
AdipoR2 seems to be an intermediate-afﬁnity receptor. In
addition, AdipoR1 and AdipoR2 may form both homo- and
heteromultimers (28). It has been shown that the relative
abundance of hybrids of the insulin and insulin-like growth
factor-I receptors is higher in diabetic patients and asso-
ciated with reduced insulin binding afﬁnity (47). There-
fore, it could be speculated that lack of adiponectin
receptor heteromultimers in the AdipoR2
/ mice may
lead to an improved AdipoR1 signaling. Moreover, plasma
adiponectin levels were increased or tended to be in-
creased in AdipoR2
/ mice, and recently an SNP cluster
in ADIPOR2 was shown to be associated with higher
adiponectin levels in humans (46). Thus, decreased
AdipoR2 expression may lead to increased adiponectin
secretion, which together with increased AdipoR1 signal-
ing may be protective against HFD-induced metabolic
alterations. However, improved basal PPAR or AMPK
signaling was not detected in AdipoR2
/ mice, indicating
that other signaling pathways are involved or that the
phenotype of AdipoR2
/ mice is explained by another
mechanism.
In summary, this study shows for the ﬁrst time that the
adiponectin receptors (28) are involved in the control of
glucose, fat, and energy metabolism in vivo. AdipoR1
deﬁciency resulted in increased adiposity associated with
decreased glucose tolerance, physical activity, and energy
expenditure, effects that in part overlap the described
phenotype of adiponectin-deﬁcient mice (22,27). On the
other hand, AdipoR2 deﬁciency resulted in resistance to
HFD-induced obesity and glucose intolerance associated
with increased physical activity and energy expenditure and
decreased plasma cholesterol levels. Another remarkable
effect of AdipoR2 deﬁciency was increased brain size, show-
ing the importance of this receptor for brain development.
Thus, activating AdipoR1 or antagonizing AdipoR2 may be
attractive therapeutic approaches for treatment of obesity,
type 2 diabetes, and cardiovascular disease.
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